Cargando…

Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review

BACKGROUND: Juvenile idiopathic arthritis (JIA) is a common rheumatic disease in children and adolescents. Although JIA may cause secondary amyloidosis, this is a rare complication in patients with JIA and other rheumatic diseases. Many previous studies have revealed that common heterozygous or homo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chantarogh, Songkiat, Vilaiyuk, Soamarat, Tim-Aroon, Thipwimol, Worawichawong, Suchin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429510/ https://www.ncbi.nlm.nih.gov/pubmed/28499374 http://dx.doi.org/10.1186/s12882-017-0573-y

Ejemplares similares

The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2014)

Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab
por: Vilaiyuk, Soamarat, et al.
Publicado: (2019)

Glucose metabolism in systemic juvenile idiopathic arthritis
por: Suppasit, Papatsorn, et al.
Publicado: (2022)

Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand
por: Kittiratchakool, Nitichen, et al.
Publicado: (2020)

Effect of educational brochure compared with video on disease-related knowledge in patients with juvenile idiopathic arthritis: A randomized controlled trial
por: Sunthornsup, Waraporn, et al.
Publicado: (2022)

Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome – effective treatment with tocilizumab
por: Kwiatkowska, Małgorzata, et al.
Publicado: (2015)

PReS-FINAL-2104: Disease course and predictors of outcome in systemic onset juvenile idiopathic arthritis
por: Soponkanaporn, S, et al.
Publicado: (2013)

Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis
por: He, Tingyan, et al.
Publicado: (2023)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
por: Alexeeva, E, et al.
Publicado: (2011)

The use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
por: Goran, Ristic, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011)

Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience
por: Roszkiewicz, Justyna, et al.
Publicado: (2018)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012)

The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Vilaiyuk, Soamarat, et al.
Publicado: (2018)

Associations of lymphocyte subpopulations with clinical phenotypes and long-term outcomes in juvenile-onset systemic lupus erythematosus
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2022)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis
por: Herlin, Troels
Publicado: (2010)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Tocilizumab for juvenile idiopathic arthritis: a single-center case series
por: Yazılıtaş, Fatma, et al.
Publicado: (2020)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
por: Iannone, Claudia, et al.
Publicado: (2023)

Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis
por: Trincianti, Chiara, et al.
Publicado: (2021)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

Effects of antirheumatic treatment with tocilizumab on longitudinal growth in children with juvenile idiopathic arthritis
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

Tocilizumab therapy in systemic juvenile idiopathic arthritis – lessons of real clinical practice
por: Kaleda, Maria I, et al.
Publicado: (2014)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

Evaluating performance of the 2019 EULAR/ACR, 2012 SLICC, and 1997 ACR criteria for classifying adult-onset and childhood-onset systemic lupus erythematosus: A systematic review and meta-analysis
por: Lerkvaleekul, Butsabong, et al.
Publicado: (2022)

PCR-based versus conventional stool tests in children with diarrhea who underwent solid organ transplantation or hematopoietic stem cell transplantation
por: Sidafong, Seewalee, et al.
Publicado: (2023)

Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report
por: Zhang, Ye, et al.
Publicado: (2022)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis
por: De La Torre, Miguel, et al.
Publicado: (2011)

Epidemiology and Outcomes of Early-Onset and Late-Onset Adenovirus Infections in Kidney Transplant Recipients
por: Bruminhent, Jackrapong, et al.
Publicado: (2019)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
por: Yamaguchi, Ken-ichi, et al.
Publicado: (2012)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)

O15 Recognition of subclinical macrophage activation syndrome in an adolescent systemic juvenile idiopathic arthritis patient receiving tocilizumab: a case report
por: Ng, Sue, et al.
Publicado: (2020)

Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis
por: Kostik, Mikhail M, et al.
Publicado: (2015)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Shimizu, Masaki, et al.
Publicado: (2020)

Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease
por: Yan, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_11mf5a9h56s9s1dfkpivmm04q7